No material signal from this routine tax-withholding sale. Monitor for any future discretionary insider sales or changes in insider ownership patterns.
TARS drugs
TARS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 17 $62.55entry
- T+1 · 5mo ago +0.98%α +0.20% · $63.16
- T+5 · 5mo ago +7.29%α +8.33% · $67.11
- T+20 · 4mo ago −7.77%α −9.09% · $57.69
- T+60 · 2mo ago +26.79%α +23.65% · $79.31
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Officer Jeffrey S. Farrow filed a Form 144 to sell 14,396 shares of Tarsus Pharmaceuticals common stock, valued at approximately $877K, to cover tax obligations from restricted stock vesting. This is a routine sell-to-cover transaction, not a discretionary sale, and carries no bearish signal.
Key Facts
- Insider Jeffrey S. Farrow (Officer) filed Form 144 to sell 14,396 shares.
- Estimated sale value: $877,459.23 based on a price of ~$60.96/share.
- Shares originate from restricted stock vesting on June 15, 2026.
- Sale is to cover tax withholding obligations, not a discretionary cash-out.
- Prior small sales in March 2026 were also tax-related (2,111–2,186 shares each).
- Sale represents ~0.03% of TARS's $2.7B market cap, immaterial.
Financial Impact
~$877K sale, 0.03% of market cap, tax-motivated
Risk Factors
- None directly from this filing; routine insider transaction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-004721 |
| Document: 0001959173-26-004721-index.html | 0001959173-26-004721 |
| Document: 0001959173-26-004721.txt | 0001959173-26-004721 |
Track record
21 reports on TARS
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers